HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $20 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Foghorn Therapeutics (NASDAQ:FHTX) and maintained a $20 price target.
August 07, 2023 | 10:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Foghorn Therapeutics' stock may see positive movement as HC Wainwright & Co. has reiterated a 'Buy' rating and maintained a $20 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a maintained price target of $20 by HC Wainwright & Co. suggests a positive outlook for Foghorn Therapeutics, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100